Mice that inherit a mutant allele of the Apc gene develop tumors principally in the small intestine (SI), unlike patients with familial polyposis (FAP) who develop large bowel cancer. However, the applicant has shown that several mouse models are not refractory to large bowel tumor formation. This application focuses on mechanisms regulating the ability of sulindac, an NSAID to stimulate the formation of large bowel tumors in the Apc1638, ApcMin, and ApcMlh1 mouse models, even though it has an inhibitory effect on tumor formation of the SI. This is similar to reports that patients given sulindac develop rectal tumors. The applicant proposes to utilize the Apc1638, ApcMin, and ApcMlh1 models to determine mechanisms by which probability of tumor formation is modulated at different sites in the intestine by sulindac and celecoxib, a specific Cox-2 inhibitor. A significant aspect of the experimental design is that alterations on a cellular, biochemical and molecular level will be assayed in regions of the intestinal tract undergoing both increases and decreases in tumor formation in the same mouse. Detailed immunohistopathology of tumor formation will include analysis of proliferation and apoptosis in the mucosa and tumors. In addition, Cox-1, Cox-2, arachidonic acid metabolism, and beta-catenin-Tcf signaling will be monitored to determine the role of these pathways in site-specific modulation of tumorigenesis. Lastly, using microarray analyses, the profiles of gene expression that characterize genetic and dietary modulation of risk will be defined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA087559-04
Application #
6701754
Study Section
Special Emphasis Panel (ZRG1-ET-2 (03))
Program Officer
Seifried, Harold E
Project Start
2001-03-01
Project End
2005-02-28
Budget Start
2004-03-01
Budget End
2005-02-28
Support Year
4
Fiscal Year
2004
Total Cost
$230,508
Indirect Cost
Name
Montefiore Medical Center (Bronx, NY)
Department
Type
DUNS #
041581026
City
New York
State
NY
Country
United States
Zip Code
10467
Itano, Osamu; Yang, Kan; Fan, Kunhua et al. (2009) Sulindac effects on inflammation and tumorigenesis in the intestine of mice with Apc and Mlh1 mutations. Carcinogenesis 30:1923-6
Yang, WanCai; Bancroft, Laura; Augenlicht, Leonard H (2005) Methylation in the p21WAF1/cip1 promoter of Apc+/-, p21+/- mice and lack of response to sulindac. Oncogene 24:2104-9
Yang, Wancai; Velcich, Anna; Lozonschi, Ioana et al. (2005) Inactivation of p21WAF1/cip1 enhances intestinal tumor formation in Muc2-/- mice. Am J Pathol 166:1239-46
Pretlow, Theresa P; Edelmann, Winfried; Kucherlapati, Raju et al. (2003) Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele. Am J Pathol 163:1757-63
Augenlicht, Leonard H; Velcich, Anna; Klampfer, Lidija et al. (2003) Application of gene expression profiling to colon cell maturation, transformation and chemoprevention. J Nutr 133:2410S-2416S
Yang, Kan; Fan, Kunhua; Kurihara, Naoto et al. (2003) Regional response leading to tumorigenesis after sulindac in small and large intestine of mice with Apc mutations. Carcinogenesis 24:605-11
Yang, WanCai; Bancroft, Laura; Nicholas, Courtney et al. (2003) Targeted inactivation of p27kip1 is sufficient for large and small intestinal tumorigenesis in the mouse, which can be augmented by a Western-style high-risk diet. Cancer Res 63:4990-6